Changeflow GovPing Energy NRC ACMUI Meeting April 20-21 on Medical Isotopes
Routine Notice Added Final

NRC ACMUI Meeting April 20-21 on Medical Isotopes

Email

Summary

The Nuclear Regulatory Commission announced an Advisory Committee on the Medical Uses of Isotopes (ACMUI) meeting scheduled for April 20-21, 2026. Agenda topics include review of medical events, ADVANCE Act implementation recommendations, alpha nuclides in radiopharmaceutical therapy, AI applications for NRC staff, and physical protection requirements for radioactive materials. Written statements must be submitted by April 13, 2026.

What changed

The NRC published a notice announcing the upcoming Advisory Committee on the Medical Uses of Isotopes (ACMUI) meeting on April 20-21, 2026. The meeting will cover medical events review, ADVANCE Act implementation, licensing recommendations for alpha nuclides in radiopharmaceutical therapy, AI applications, and proposed rulemaking on physical protection of radioactive materials.\n\nHealthcare providers, radiopharmaceutical manufacturers, and medical isotope licensees should monitor this meeting for guidance developments and potential regulatory updates affecting medical isotope use under 10 CFR Part 35. Written public comments on agenda topics may be submitted through April 13, 2026.

What to do next

  1. Submit written statements to Ms. A. Marra by April 13, 2026 to participate in the meeting
  2. Monitor the ACMUI Meetings page for agenda updates
  3. Register via Microsoft Teams or phone to attend the public webinar

Archived snapshot

Apr 9, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

ACTION:

Notice of meeting.

SUMMARY:

The U.S. Nuclear Regulatory Commission (NRC) will convene a meeting of the Advisory Committee on the Medical Uses of Isotopes
(ACMUI) on April 20-21, 2026. A sample of agenda items to be discussed include: a review of recent medical events; recommendations
and advice to support the NRC implementation of the ADVANCE Act; recommendations on the staff's memo for licensing the use
of alpha nuclides in radiopharmaceutical therapy; recommendations on the potential applications of artificial intelligence
(AI) and deep learning technologies to enhance the efficiency and effectiveness of the NRC medical staff and the ACMUI; recommended
best practices for the preparation of reports, including guidance on writing subcommittee reports and developing effective
presentations, including Commission presentations; assessment of ACMUI membership to determine if the ACMUI would like to
propose a change in membership to include an interventional radiologist; ACMUI review and recommendations regarding staff's
proposed rulemaking on modernizing requirements relating to physical protection of category 1 and category 2 quantities of
radioactive material rulemaking (topic is tentative based on its rulemaking schedule); and NRC's medical radiation safety team updates.

FOR FURTHER INFORMATION CONTACT:

Ms. A. Marra, email: Alessandra.Marra@nrc.gov, telephone: 301-415-2509.

SUPPLEMENTARY INFORMATION:

The agenda is subject to change. The current agenda and any updates will be available on the ACMUI's Meetings and

  Related Documents web page at *https://www.nrc.gov/reading-rm/doc-collections/acmui/meetings/index.html* or by emailing Ms. A. Marra at the contact information below.

Purpose: Discuss issues related to 10 CFR part 35 Medical Use of Byproduct Material.

Date and Time for Open Sessions: April 20, 2026, from 9:00 a.m. to 5:00 p.m. and April 21, 2026, from 10:00 a.m. to 1:15 p.m. Eastern Standard Time.

Date Webinar information (Microsoft Teams)
April 20, 2026 Join: https://teams.microsoft.com/meet/27605721107301?p=NME89xbyHXSK32XAUI.
Meeting ID: 276 057 211 073 01.Passcode: yF7DP3ri.
Call in number (audio only): +1 301-576-2978,,558206708#.
Phone Conference ID: 558 206 708#.

Public Participation: The meeting will be held as a webinar using Microsoft Teams. Any member of the public who wishes to participate in the meeting
via Microsoft Teams or via phone should contact Ms. A. Marra using the information below. Members of the public should also
monitor the NRC's Public Meeting Schedule at https://www.nrc.gov/pmns/mtg for any meeting updates.

Conduct of the Meeting: The ACMUI Chair, Hossein Jadvar, M.D., Ph.D. will preside over the meeting. Dr. Jadvar will conduct the meeting in a manner
that will facilitate the orderly conduct of business. The following procedures apply to public participation in the meeting:

  1. Persons who wish to provide a written statement should submit an electronic copy to Ms. A. Marra using the contact information
    listed above. All submittals must be received by the close of business on April 13, 2026, and must only pertain to the topics
    on the agenda.

  2. Questions and comments from members of the public to the ACMUI will be permitted during the meeting, at the discretion
    of the ACMUI Chair.

  3. The draft transcript and meeting summary will be available on ACMUI's website https://www.nrc.gov/reading-rm/doc-collections/acmui/meetings/2024.html on or about May 28, 2026.

  4. Persons who require special services, such as those for the hearing impaired, should notify Ms. A. Marra of their planned
    participation.

This meeting will be held in accordance with the Atomic Energy Act of 1954, as amended (primarily Section 161a); the Federal
Advisory Committee Act (5 U.S.C. App); and the Commission's regulations in title 10 of the Code of Federal Regulations, Part 7.

Dated at Rockville, Maryland, this 6th day of April, 2026. For the U.S. Nuclear Regulatory Commission.

Russell E. Chazell, Federal Advisory Committee Management Officer. [FR Doc. 2026-06807 Filed 4-8-26; 8:45 am] BILLING CODE 7590-01-P

Download File

Download

CFR references

10 CFR Part 35

Named provisions

Medical Use of Byproduct Material ADVANCE Act Implementation Physical Protection of Category 1 and 2 Radioactive Material

Get daily alerts for Regs.gov: Nuclear Regulatory Commission

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NRC.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NRC
Comment period closes
April 13th, 2026 (closed 3 days ago)
Compliance deadline
April 13th, 2026 (3 days ago)
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NRC-2026-0003-0001
Docket
NRC-2026-0003

Who this affects

Applies to
Healthcare providers Government agencies Medical device makers
Industry sector
6211 Healthcare Providers
Activity scope
Medical isotope licensing Radiopharmaceutical regulation Advisory committee meetings
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Nuclear Artificial Intelligence

Get alerts for this source

We'll email you when Regs.gov: Nuclear Regulatory Commission publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!